Carbonic anhydrase IX (CA IX) is a recently validated target for the development of new cancer therapies. In this paper we describe the synthesis and CA inhibition of a novel series of carbohydrate-based 1,5-disubstituted-1,2,3-triazole benzenesulfonamides. The key step of our synthesis is the regioselective Huisgen's 1,3-dipolar cycloaddition reaction (1,3-DCR) from carbohydrate azide substrates and 4-ethynylbenzenesulfonamide using a ruthenium-catalysed azide-alkyne cycloaddition (RuAAC). Our findings identified a number of triazole inhibitors (compounds 18, 19, 21-23 and 26) that block CA IX activity with inhibition constants less than 10 nM. One inhibitor (compound 17) possessed very good selectivity for CA
upregulated in a wide variety of hypoxic tumors, while expression is typically absent in healthy cells (with the exception of cells in the stomach and gastrointestinal tract). 3, 4 CA IX underpins a robust pH-regulating system that allows tumor cells growing in a hypoxic and acidic microenvironment to survive and proliferate. 5 The topology of CA IX comprises an extracellular catalytic domain, this differs to the ubiquitously expressed, off-target CA II which is a soluble, cytosolic enzyme. 2 CA IX inhibitor development requires balancing potency, selectivity and physicochemical properties that are needed to be useful in vivo, allowing the inhibitor to find and interact with CA IX to elicit the desired pharmacological response. The tumor-selective expression of CA IX together with the extracellular localisation of its active site enhances the druggability prospects for CA IX as a molecular target for small molecule inhibitors.
The role of medicinal chemistry in the CA field is to develop small molecule inhibitors within this framework. The CA active site comprises a tetrahedral Zn 2+ cation that plays both a structural and a catalytic role and is the implied target for drug design. Almost all reported small molecule CA inhibitors comprise a zinc binding group (ZBG) and a 'tail' group. 2 The primary sulfonamide moiety (-SO 2 NH 2 ) is the foremost example of a ZBG for CA inhibitors. The 'tail' approach for CA inhibitor development was first described by Supuran and co-workers. 6 Appending tail groups to an ArSO 2 NH 2 ZBG has proven effective in enhancing physicochemical properties such as lipophilicity, solubility, permeability, stability and cytotoxicity for a large number of CA inhibitors. 7 , 8, 9 CA inhibitors that incorporate a hydrophilic moiety such as a cationic pyridinium 10, 11 and 'Cp*Ru(II)' salts, 12 metal-chelating agents, [13] [14] [15] or carbohydrate moieties [16] [17] [18] [19] [20] [21] have been developed. These compounds have limited membrane permeability and so may better target CA IX over CA II. The attachment of the tail moiety to the Ar-SO 2 NH 2 CA anchor has been achieved using straightforward chemistry to form covalent links such as esters, amides, imines, ureas and thioureas.
Our research group has demonstrated the versatility of the 1,3-dipolar cycloaddition reaction (1,3-DCR) of organic azides (R-N 3 ) with alkynes (R′-C≡CH), i.e. the Huisgen reaction, 22 to form 1,2,3-triazole glycoconjugate CA inhibitors. 9 Both Meldal 23 and Sharpless 24 discovered that catalytic Cu(I) leads to a dramatic rate enhancement (up to 10 7 -fold) and synthesis of the 1,4-disubstituted-1,2,3-triazole product. The reaction is now referred to as the copper-catalysed azide-alkyne cycloaddition (CuAAC) and has rapidly become the premier click chemistry reaction. 25, 26 The regioselective synthesis of the other possible product from (1,3-DCR), the 1,5-disubstituted-1,2,3-triazole, has been achieved more recently by catalysis with ruthenium complexes such as [Cp*RuCl(PPh 3 ) 2 ] under relatively mild conditions. 27 The 1,2,3-triazole mimics a peptide bond but is chemically robust in vivo, hence the adoption of this moiety into medicinal chemistry research programs. 26, 28 The triazole moiety can either play a passive or active role when incorporated into a pharmacophore. When operating passively the triazole provides a non-labile covalent spacer between discrete N-1 and C-4 or C-5 substituents. Alternatively, when operating in an active capacity the triazole participates through direct interactions with the biological target. 26 While applications of CuAAC in medicinal chemistry abound, 25, [28] [29] [30] to date there remains relatively few applications of RuAAC. [31] [32] [33] [34] [35] [36] [37] [38] [39] Our group has previously developed membrane impermeable carbohydratebased CA inhibitors from azido sugars 2-6 ( Figure 1a ) and pethynylbenzenesulfonamide 1 using CuAAC to generate 1,4-disubstituted-1,2,3triazole benzenesulfonamides 7-16, Figure 2b . 19 In another study we reacted organometallic ferrocenyl and ruthenocenyl alkynes with p-azidobenzenesulfonamide using both CuAAC and RuAAC to generate 1,4-and 1,5-disubstitituted 1,2,3-triazole benzenesulfonamide compounds, respectively, to the best of our knowledge the first medicinal chemistry application utilising the regioselective RuAAC, Figure 2c . 39 We found that the differing orientation of the metallocene moiety relative to the benzenesulfonamide moiety impacted on both potency and CA isozyme selectivity. In these compounds the 1,4-disubstituted triazole regioisomer had better CA IX selectivity than the 1,5-disubstituted triazole regioisomer. In the present study our intention is to build upon SAR generated from carbohydratebased triazole CA inhibitors prepared with CuAAC 19 by applying the 'reverse regioselectivity' RuAAC reaction conditions to generate a corresponding library of 1- Optimisation of the RuAAC reaction conditions was performed by studying the synthesis of the 1,5-disubstituted-1,2,3-triazole 17 from azide 2 and p-ethynylbenzenesulfonamide 1. Reaction conditions were adapted from those reported by Zhang and co-workers using [Cp*RuCl(PPh 3 ) 2 ] as catalyst. 27 We observed that an increase in catalyst loading and/or reaction time results in an improved reaction yield ( Table 1 , entries 1-3), however yields are low.
Decomposition of the catalyst to a tetraazadiene may in part account for the low yields. 40 In addition triphenylphosphine and triphenylphosphine oxide (formed from oxidation of triphenylphosphine ligands) proved difficult to separate from the target triazole compound during purification. Boren and co-workers reported a study of [Cp*RuCl(PPh 3 ) 2 ] and [Cp*RuCl(cod)] catalysts in the RuAAC synthesis of 1,5-disubstituted-1,2,3-triazoles. 40 These catalysts share the same mechanism, however the cod (cyclooctadiene) ligand of [Cp*RuCl(cod)] is more labile than the triphenylphosphine ligand of [Cp*RuCl(PPh 3 ) 2 ], and this resulted in higher reactivity and reaction yields. 40 We explored the use of [Cp*RuCl(cod)] to synthesise 17 as an alternate 'Cp*RuCl' catalyst. Our findings were consistent with those reported, a comparison of Table 1 , entries 2 and 4 shows the yield improves from 25% to 42% 24 n/a n/a n/a n/a n/a opposite to that observed with the hydrophobic metallocene tail moieties. 39 In these compounds the 1,4-disubstituted triazole regioisomer had better CA IX selectivity than the 1,5-disubstituted triazole regioisomer. 39 As the CA active site encompasses two distinct regions to which the CA inhibitor tail can potentially interact, one lined by hydrophobic amino acids (consisting of Phe 130 , Val 134 , Leu 203 and Pro 201 ) and the other located directly opposite and lined by hydrophilic amino acids (primarily Asn 62 , Asn 67 and Gln 92 ), 2 it is logical that hydrophobic versus hydrophilic tail groups may lead to differential isozyme selectivity.
In summary the new compounds of this study comprise a sugar moiety tethered to an aromatic sulfonamide CA pharmacophore through an intervening triazole ring. Table 2 . Inhibition and isozyme selectivity ratio data of CA isozymes I, II, and IX with triazoles 7-26, compound 1, and the established drug and CA inhibitor, AZA.
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